August 23, 2010 - Calypso Medical Technologies Inc., entered into a distribution agreement with Siemens Healthcare for the sale of its Calypso System in Europe.
The Calypso System is a real-time localization technology used for the precise tracking of tumor targets.
“This agreement extends the availability of our GPS for the Body technology into geographic areas with significant incidences of prostate cancer," said Jed Palmacci, vice president of global sales for Calypso Medical.
Under terms of the agreement, Siemens retains nonexclusive rights to sell Calypso’s real-time tracking technology to existing and prospective Siemens linear accelerator customers throughout Europe for a period of three years.
Last year Calypso Medical entered into a master development agreement (MDA) with Siemens to jointly develop products integrating the Calypso System with the Siemens ARTISTE linear accelerator and other Siemens radiotherapy technologies.
With recent clinical findings of improved outcomes, Calypso's GPS for the Body technology enables doctors to localize and track the tumor before and during each radiation treatment. When the tumor moves outside of the field of radiation, therapy can be stopped while the patient is repositioned to ensure that the tumor, not surrounding healthy tissue, receives the radiation dose.
In contrast to other tumor targeting solutions, the Calypso System provides continuous tumor position information, objectively and without ionizing radiation, thereby safeguarding the patient from an additional nontherapeutic radiation dose.